Cardiff Oncology, Inc.
Cardiff Oncology, Inc. (CRDF) Stock Competitors & Peer Comparison
See (CRDF) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CRDF | $2.51 | -4.92% | 167M | -2.89 | -$0.87 | N/A |
| VRTX | $472.27 | +2.19% | 121.3B | -122.99 | -$3.84 | N/A |
| REGN | $571.54 | +2.27% | 60.7B | 14.40 | $39.68 | +0.31% |
| ALNY | $419.56 | +4.42% | 55B | -171.25 | -$2.45 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ARGX | $690.32 | +2.45% | 42.2B | 35.18 | $19.62 | N/A |
| BNTX | $110.03 | +2.51% | 26.5B | -30.19 | -$3.65 | N/A |
| SMMT | $29.32 | +8.31% | 21.8B | -86.24 | -$0.34 | N/A |
| RPRX | $37.88 | +2.07% | 21.3B | 15.46 | $2.45 | +2.28% |
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
Stock Comparison
CRDF vs VRTX Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, VRTX has a market cap of 121.3B. Regarding current trading prices, CRDF is priced at $2.51, while VRTX trades at $472.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas VRTX's P/E ratio is -122.99. In terms of profitability, CRDF's ROE is -0.78%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, CRDF is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check VRTX's competition here
CRDF vs REGN Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, REGN has a market cap of 60.7B. Regarding current trading prices, CRDF is priced at $2.51, while REGN trades at $571.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas REGN's P/E ratio is 14.40. In terms of profitability, CRDF's ROE is -0.78%, compared to REGN's ROE of +0.14%. Regarding short-term risk, CRDF is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check REGN's competition here
CRDF vs ALNY Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, ALNY has a market cap of 55B. Regarding current trading prices, CRDF is priced at $2.51, while ALNY trades at $419.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas ALNY's P/E ratio is -171.25. In terms of profitability, CRDF's ROE is -0.78%, compared to ALNY's ROE of -2.74%. Regarding short-term risk, CRDF is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check ALNY's competition here
CRDF vs SGEN Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, CRDF is priced at $2.51, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas SGEN's P/E ratio is -57.19. In terms of profitability, CRDF's ROE is -0.78%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, CRDF is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check SGEN's competition here
CRDF vs ARGX Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, ARGX has a market cap of 42.2B. Regarding current trading prices, CRDF is priced at $2.51, while ARGX trades at $690.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas ARGX's P/E ratio is 35.18. In terms of profitability, CRDF's ROE is -0.78%, compared to ARGX's ROE of +0.23%. Regarding short-term risk, CRDF is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check ARGX's competition here
CRDF vs BNTX Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, BNTX has a market cap of 26.5B. Regarding current trading prices, CRDF is priced at $2.51, while BNTX trades at $110.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas BNTX's P/E ratio is -30.19. In terms of profitability, CRDF's ROE is -0.78%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, CRDF is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check BNTX's competition here
CRDF vs SMMT Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, SMMT has a market cap of 21.8B. Regarding current trading prices, CRDF is priced at $2.51, while SMMT trades at $29.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas SMMT's P/E ratio is -86.24. In terms of profitability, CRDF's ROE is -0.78%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, CRDF is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for CRDF.Check SMMT's competition here
CRDF vs RPRX Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, RPRX has a market cap of 21.3B. Regarding current trading prices, CRDF is priced at $2.51, while RPRX trades at $37.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas RPRX's P/E ratio is 15.46. In terms of profitability, CRDF's ROE is -0.78%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, CRDF is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check RPRX's competition here
CRDF vs BGNE Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, CRDF is priced at $2.51, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas BGNE's P/E ratio is -22.55. In terms of profitability, CRDF's ROE is -0.78%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, CRDF is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check BGNE's competition here
CRDF vs DNA-WT Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, CRDF is priced at $2.51, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, CRDF's ROE is -0.78%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, CRDF is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check DNA-WT's competition here
CRDF vs INCY Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, INCY has a market cap of 15.2B. Regarding current trading prices, CRDF is priced at $2.51, while INCY trades at $78.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas INCY's P/E ratio is 18.45. In terms of profitability, CRDF's ROE is -0.78%, compared to INCY's ROE of +0.34%. Regarding short-term risk, CRDF is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check INCY's competition here
CRDF vs GMAB Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, GMAB has a market cap of 13.5B. Regarding current trading prices, CRDF is priced at $2.51, while GMAB trades at $21.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas GMAB's P/E ratio is 12.93. In terms of profitability, CRDF's ROE is -0.78%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, CRDF is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check GMAB's competition here
CRDF vs UTHR Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, UTHR has a market cap of 13.2B. Regarding current trading prices, CRDF is priced at $2.51, while UTHR trades at $292.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas UTHR's P/E ratio is 11.41. In terms of profitability, CRDF's ROE is -0.78%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, CRDF is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check UTHR's competition here
CRDF vs KRTX Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, CRDF is priced at $2.51, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas KRTX's P/E ratio is -28.09. In terms of profitability, CRDF's ROE is -0.78%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, CRDF is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check KRTX's competition here
CRDF vs BMRN Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, BMRN has a market cap of 11.6B. Regarding current trading prices, CRDF is priced at $2.51, while BMRN trades at $60.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas BMRN's P/E ratio is 22.34. In terms of profitability, CRDF's ROE is -0.78%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, CRDF is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check BMRN's competition here
CRDF vs ASND Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, ASND has a market cap of 11.1B. Regarding current trading prices, CRDF is priced at $2.51, while ASND trades at $184.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas ASND's P/E ratio is -27.69. In terms of profitability, CRDF's ROE is -0.78%, compared to ASND's ROE of +1.91%. Regarding short-term risk, CRDF is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check ASND's competition here
CRDF vs MRNA Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, MRNA has a market cap of 10.7B. Regarding current trading prices, CRDF is priced at $2.51, while MRNA trades at $27.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas MRNA's P/E ratio is -3.68. In terms of profitability, CRDF's ROE is -0.78%, compared to MRNA's ROE of -0.27%. Regarding short-term risk, CRDF is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check MRNA's competition here
CRDF vs EXEL Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, EXEL has a market cap of 9.9B. Regarding current trading prices, CRDF is priced at $2.51, while EXEL trades at $36.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas EXEL's P/E ratio is 17.70. In terms of profitability, CRDF's ROE is -0.78%, compared to EXEL's ROE of +0.28%. Regarding short-term risk, CRDF is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check EXEL's competition here
CRDF vs RXDX Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, CRDF is priced at $2.51, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas RXDX's P/E ratio is -56.47. In terms of profitability, CRDF's ROE is -0.78%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, CRDF is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check RXDX's competition here
CRDF vs BBIO Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, BBIO has a market cap of 9.1B. Regarding current trading prices, CRDF is priced at $2.51, while BBIO trades at $47.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas BBIO's P/E ratio is -13.41. In terms of profitability, CRDF's ROE is -0.78%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, CRDF is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check BBIO's competition here
CRDF vs VRNA Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, VRNA has a market cap of 9B. Regarding current trading prices, CRDF is priced at $2.51, while VRNA trades at $105.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas VRNA's P/E ratio is -52.73. In terms of profitability, CRDF's ROE is -0.78%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, CRDF is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check VRNA's competition here
CRDF vs IMGN Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, CRDF is priced at $2.51, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas IMGN's P/E ratio is -111.55. In terms of profitability, CRDF's ROE is -0.78%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, CRDF is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check IMGN's competition here
CRDF vs TECH Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, TECH has a market cap of 8.6B. Regarding current trading prices, CRDF is priced at $2.51, while TECH trades at $54.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas TECH's P/E ratio is 66.12. In terms of profitability, CRDF's ROE is -0.78%, compared to TECH's ROE of +0.06%. Regarding short-term risk, CRDF is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check TECH's competition here
CRDF vs BPMC Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, CRDF is priced at $2.51, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas BPMC's P/E ratio is -51.58. In terms of profitability, CRDF's ROE is -0.78%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, CRDF is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check BPMC's competition here
CRDF vs CERE Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, CRDF is priced at $2.51, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas CERE's P/E ratio is -16.47. In terms of profitability, CRDF's ROE is -0.78%, compared to CERE's ROE of -0.43%. Regarding short-term risk, CRDF is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check CERE's competition here
CRDF vs ROIVW Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, CRDF is priced at $2.51, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, CRDF's ROE is -0.78%, compared to ROIVW's ROE of -0.03%. Regarding short-term risk, CRDF is more volatile compared to ROIVW. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check ROIVW's competition here
CRDF vs ROIV Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, ROIV has a market cap of 7.8B. Regarding current trading prices, CRDF is priced at $2.51, while ROIV trades at $11.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas ROIV's P/E ratio is -15.35. In terms of profitability, CRDF's ROE is -0.78%, compared to ROIV's ROE of -0.03%. Regarding short-term risk, CRDF is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check ROIV's competition here
CRDF vs CORT Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, CORT has a market cap of 7.6B. Regarding current trading prices, CRDF is priced at $2.51, while CORT trades at $71.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas CORT's P/E ratio is 64.08. In terms of profitability, CRDF's ROE is -0.78%, compared to CORT's ROE of +0.20%. Regarding short-term risk, CRDF is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check CORT's competition here
CRDF vs HALO Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, HALO has a market cap of 7.4B. Regarding current trading prices, CRDF is priced at $2.51, while HALO trades at $59.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas HALO's P/E ratio is 15.95. In terms of profitability, CRDF's ROE is -0.78%, compared to HALO's ROE of +1.22%. Regarding short-term risk, CRDF is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check HALO's competition here
CRDF vs JAZZ Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, JAZZ has a market cap of 7B. Regarding current trading prices, CRDF is priced at $2.51, while JAZZ trades at $116.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas JAZZ's P/E ratio is 15.77. In terms of profitability, CRDF's ROE is -0.78%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, CRDF is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check JAZZ's competition here
CRDF vs MDGL Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, MDGL has a market cap of 6.9B. Regarding current trading prices, CRDF is priced at $2.51, while MDGL trades at $312.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas MDGL's P/E ratio is -17.49. In terms of profitability, CRDF's ROE is -0.78%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, CRDF is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check MDGL's competition here
CRDF vs IONS Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, IONS has a market cap of 6.9B. Regarding current trading prices, CRDF is priced at $2.51, while IONS trades at $43.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas IONS's P/E ratio is -24.69. In terms of profitability, CRDF's ROE is -0.78%, compared to IONS's ROE of -0.45%. Regarding short-term risk, CRDF is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check IONS's competition here
CRDF vs RVMD Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, RVMD has a market cap of 6.9B. Regarding current trading prices, CRDF is priced at $2.51, while RVMD trades at $37.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas RVMD's P/E ratio is -9.27. In terms of profitability, CRDF's ROE is -0.78%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, CRDF is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check RVMD's competition here
CRDF vs RETA Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, CRDF is priced at $2.51, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas RETA's P/E ratio is -66.29. In terms of profitability, CRDF's ROE is -0.78%, compared to RETA's ROE of +0.47%. Regarding short-term risk, CRDF is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check RETA's competition here
CRDF vs RYTM Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, RYTM has a market cap of 5.9B. Regarding current trading prices, CRDF is priced at $2.51, while RYTM trades at $90.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas RYTM's P/E ratio is -32.23. In terms of profitability, CRDF's ROE is -0.78%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, CRDF is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check RYTM's competition here
CRDF vs NUVL Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, NUVL has a market cap of 5.6B. Regarding current trading prices, CRDF is priced at $2.51, while NUVL trades at $78.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas NUVL's P/E ratio is -17.74. In terms of profitability, CRDF's ROE is -0.78%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, CRDF is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check NUVL's competition here
CRDF vs ABCM Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, CRDF is priced at $2.51, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, CRDF's ROE is -0.78%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, CRDF is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check ABCM's competition here
CRDF vs ISEE Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, CRDF is priced at $2.51, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas ISEE's P/E ratio is -22.44. In terms of profitability, CRDF's ROE is -0.78%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, CRDF is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check ISEE's competition here
CRDF vs ABVX Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, ABVX has a market cap of 5.4B. Regarding current trading prices, CRDF is priced at $2.51, while ABVX trades at $72.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas ABVX's P/E ratio is -21.39. In terms of profitability, CRDF's ROE is -0.78%, compared to ABVX's ROE of -1.06%. Regarding short-term risk, CRDF is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check ABVX's competition here
CRDF vs AXSM Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, AXSM has a market cap of 5.2B. Regarding current trading prices, CRDF is priced at $2.51, while AXSM trades at $106.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas AXSM's P/E ratio is -18.46. In terms of profitability, CRDF's ROE is -0.78%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, CRDF is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for CRDF.Check AXSM's competition here
CRDF vs CRSP Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, CRSP has a market cap of 5.1B. Regarding current trading prices, CRDF is priced at $2.51, while CRSP trades at $59.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas CRSP's P/E ratio is -13.27. In terms of profitability, CRDF's ROE is -0.78%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, CRDF is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check CRSP's competition here
CRDF vs MRUS Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, MRUS has a market cap of 5B. Regarding current trading prices, CRDF is priced at $2.51, while MRUS trades at $66.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas MRUS's P/E ratio is -16.09. In terms of profitability, CRDF's ROE is -0.78%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, CRDF is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check MRUS's competition here
CRDF vs ADMA Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, ADMA has a market cap of 4.8B. Regarding current trading prices, CRDF is priced at $2.51, while ADMA trades at $19.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas ADMA's P/E ratio is 23.70. In terms of profitability, CRDF's ROE is -0.78%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, CRDF is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check ADMA's competition here
CRDF vs TGTX Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, TGTX has a market cap of 4.6B. Regarding current trading prices, CRDF is priced at $2.51, while TGTX trades at $28.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas TGTX's P/E ratio is 114.88. In terms of profitability, CRDF's ROE is -0.78%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, CRDF is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for CRDF.Check TGTX's competition here
CRDF vs TLX Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, TLX has a market cap of 4.5B. Regarding current trading prices, CRDF is priced at $2.51, while TLX trades at $13.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas TLX's P/E ratio is 148.00. In terms of profitability, CRDF's ROE is -0.78%, compared to TLX's ROE of +0.06%. Regarding short-term risk, CRDF is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check TLX's competition here
CRDF vs RNA Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, RNA has a market cap of 4.5B. Regarding current trading prices, CRDF is priced at $2.51, while RNA trades at $37.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas RNA's P/E ratio is -12.44. In terms of profitability, CRDF's ROE is -0.78%, compared to RNA's ROE of -0.27%. Regarding short-term risk, CRDF is more volatile compared to RNA. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check RNA's competition here
CRDF vs ALPN Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, CRDF is priced at $2.51, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas ALPN's P/E ratio is -101.52. In terms of profitability, CRDF's ROE is -0.78%, compared to ALPN's ROE of -0.04%. Regarding short-term risk, CRDF is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check ALPN's competition here
CRDF vs SLNO Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, SLNO has a market cap of 4.4B. Regarding current trading prices, CRDF is priced at $2.51, while SLNO trades at $84.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas SLNO's P/E ratio is -17.75. In terms of profitability, CRDF's ROE is -0.78%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, CRDF is more volatile compared to SLNO. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check SLNO's competition here
CRDF vs ALKS Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, ALKS has a market cap of 4.4B. Regarding current trading prices, CRDF is priced at $2.51, while ALKS trades at $26.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas ALKS's P/E ratio is 12.87. In terms of profitability, CRDF's ROE is -0.78%, compared to ALKS's ROE of +0.24%. Regarding short-term risk, CRDF is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check ALKS's competition here
CRDF vs CYTK Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, CYTK has a market cap of 4.4B. Regarding current trading prices, CRDF is priced at $2.51, while CYTK trades at $36.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas CYTK's P/E ratio is -6.91. In terms of profitability, CRDF's ROE is -0.78%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, CRDF is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check CYTK's competition here
CRDF vs PCVX Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, PCVX has a market cap of 4.4B. Regarding current trading prices, CRDF is priced at $2.51, while PCVX trades at $33.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas PCVX's P/E ratio is -8.45. In terms of profitability, CRDF's ROE is -0.78%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, CRDF is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check PCVX's competition here
CRDF vs ZLAB Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, ZLAB has a market cap of 4.2B. Regarding current trading prices, CRDF is priced at $2.51, while ZLAB trades at $38.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas ZLAB's P/E ratio is -15.22. In terms of profitability, CRDF's ROE is -0.78%, compared to ZLAB's ROE of -0.33%. Regarding short-term risk, CRDF is more volatile compared to ZLAB. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check ZLAB's competition here
CRDF vs OPT Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, CRDF is priced at $2.51, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas OPT's P/E ratio is -1.52. In terms of profitability, CRDF's ROE is -0.78%, compared to OPT's ROE of +2.60%. Regarding short-term risk, CRDF is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check OPT's competition here
CRDF vs PTCT Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, PTCT has a market cap of 4.1B. Regarding current trading prices, CRDF is priced at $2.51, while PTCT trades at $52.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas PTCT's P/E ratio is 8.03. In terms of profitability, CRDF's ROE is -0.78%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, CRDF is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check PTCT's competition here
CRDF vs MRTX Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, CRDF is priced at $2.51, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas MRTX's P/E ratio is -4.82. In terms of profitability, CRDF's ROE is -0.78%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, CRDF is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check MRTX's competition here
CRDF vs ACAD Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, ACAD has a market cap of 4B. Regarding current trading prices, CRDF is priced at $2.51, while ACAD trades at $24.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas ACAD's P/E ratio is 17.55. In terms of profitability, CRDF's ROE is -0.78%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, CRDF is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check ACAD's competition here
CRDF vs ACLX Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, ACLX has a market cap of 4B. Regarding current trading prices, CRDF is priced at $2.51, while ACLX trades at $72.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas ACLX's P/E ratio is -24.11. In terms of profitability, CRDF's ROE is -0.78%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, CRDF is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check ACLX's competition here
CRDF vs KRYS Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, KRYS has a market cap of 3.9B. Regarding current trading prices, CRDF is priced at $2.51, while KRYS trades at $134.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas KRYS's P/E ratio is 32.28. In terms of profitability, CRDF's ROE is -0.78%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, CRDF is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for CRDF.Check KRYS's competition here
CRDF vs AKRO Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, AKRO has a market cap of 3.9B. Regarding current trading prices, CRDF is priced at $2.51, while AKRO trades at $48.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas AKRO's P/E ratio is -12.97. In terms of profitability, CRDF's ROE is -0.78%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, CRDF is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check AKRO's competition here
CRDF vs VKTX Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, VKTX has a market cap of 3.8B. Regarding current trading prices, CRDF is priced at $2.51, while VKTX trades at $33.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas VKTX's P/E ratio is -22.06. In terms of profitability, CRDF's ROE is -0.78%, compared to VKTX's ROE of -0.20%. Regarding short-term risk, CRDF is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check VKTX's competition here
CRDF vs RYZB Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, CRDF is priced at $2.51, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas RYZB's P/E ratio is -57.86. In terms of profitability, CRDF's ROE is -0.78%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, CRDF is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check RYZB's competition here
CRDF vs CBAY Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, CRDF is priced at $2.51, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas CBAY's P/E ratio is -32.81. In terms of profitability, CRDF's ROE is -0.78%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, CRDF is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check CBAY's competition here
CRDF vs MTSR Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, MTSR has a market cap of 3.6B. Regarding current trading prices, CRDF is priced at $2.51, while MTSR trades at $34.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas MTSR's P/E ratio is -11.71. In terms of profitability, CRDF's ROE is -0.78%, compared to MTSR's ROE of -0.63%. Regarding short-term risk, CRDF is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for CRDF.Check MTSR's competition here
CRDF vs SWTX Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, CRDF is priced at $2.51, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas SWTX's P/E ratio is -13.78. In terms of profitability, CRDF's ROE is -0.78%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, CRDF is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check SWTX's competition here
CRDF vs LEGN Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, LEGN has a market cap of 3.5B. Regarding current trading prices, CRDF is priced at $2.51, while LEGN trades at $38.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas LEGN's P/E ratio is -32.58. In terms of profitability, CRDF's ROE is -0.78%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, CRDF is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check LEGN's competition here
CRDF vs SRRK Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, SRRK has a market cap of 3.5B. Regarding current trading prices, CRDF is priced at $2.51, while SRRK trades at $36.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas SRRK's P/E ratio is -14.51. In terms of profitability, CRDF's ROE is -0.78%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, CRDF is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check SRRK's competition here
CRDF vs AAPG Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, AAPG has a market cap of 3.5B. Regarding current trading prices, CRDF is priced at $2.51, while AAPG trades at $37.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas AAPG's P/E ratio is -50.13. In terms of profitability, CRDF's ROE is -0.78%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, CRDF is more volatile compared to AAPG. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check AAPG's competition here
CRDF vs MLTX Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, MLTX has a market cap of 3.4B. Regarding current trading prices, CRDF is priced at $2.51, while MLTX trades at $53.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas MLTX's P/E ratio is -23.18. In terms of profitability, CRDF's ROE is -0.78%, compared to MLTX's ROE of -0.31%. Regarding short-term risk, CRDF is more volatile compared to MLTX. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check MLTX's competition here
CRDF vs PTGX Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, PTGX has a market cap of 3.3B. Regarding current trading prices, CRDF is priced at $2.51, while PTGX trades at $53.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas PTGX's P/E ratio is 69.01. In terms of profitability, CRDF's ROE is -0.78%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, CRDF is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check PTGX's competition here
CRDF vs APLS Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, APLS has a market cap of 3.1B. Regarding current trading prices, CRDF is priced at $2.51, while APLS trades at $24.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas APLS's P/E ratio is -13.26. In terms of profitability, CRDF's ROE is -0.78%, compared to APLS's ROE of -1.16%. Regarding short-term risk, CRDF is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check APLS's competition here
CRDF vs KYMR Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, KYMR has a market cap of 3.1B. Regarding current trading prices, CRDF is priced at $2.51, while KYMR trades at $43.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas KYMR's P/E ratio is -14.04. In terms of profitability, CRDF's ROE is -0.78%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, CRDF is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check KYMR's competition here
CRDF vs MORF Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, CRDF is priced at $2.51, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas MORF's P/E ratio is -14.88. In terms of profitability, CRDF's ROE is -0.78%, compared to MORF's ROE of -0.22%. Regarding short-term risk, CRDF is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check MORF's competition here
CRDF vs MOR Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, CRDF is priced at $2.51, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas MOR's P/E ratio is -12.64. In terms of profitability, CRDF's ROE is -0.78%, compared to MOR's ROE of -1.84%. Regarding short-term risk, CRDF is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check MOR's competition here
CRDF vs IMVT Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, IMVT has a market cap of 2.8B. Regarding current trading prices, CRDF is priced at $2.51, while IMVT trades at $16.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas IMVT's P/E ratio is -5.89. In terms of profitability, CRDF's ROE is -0.78%, compared to IMVT's ROE of -0.81%. Regarding short-term risk, CRDF is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check IMVT's competition here
CRDF vs KDNY Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, CRDF is priced at $2.51, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas KDNY's P/E ratio is -12.47. In terms of profitability, CRDF's ROE is -0.78%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, CRDF is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check KDNY's competition here
CRDF vs RARE Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, RARE has a market cap of 2.7B. Regarding current trading prices, CRDF is priced at $2.51, while RARE trades at $28.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas RARE's P/E ratio is -4.88. In terms of profitability, CRDF's ROE is -0.78%, compared to RARE's ROE of -1.86%. Regarding short-term risk, CRDF is more volatile compared to RARE. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check RARE's competition here
CRDF vs CPRX Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, CPRX has a market cap of 2.7B. Regarding current trading prices, CRDF is priced at $2.51, while CPRX trades at $21.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas CPRX's P/E ratio is 13.84. In terms of profitability, CRDF's ROE is -0.78%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, CRDF is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check CPRX's competition here
CRDF vs CRNX Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, CRNX has a market cap of 2.6B. Regarding current trading prices, CRDF is priced at $2.51, while CRNX trades at $28.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas CRNX's P/E ratio is -7.43. In terms of profitability, CRDF's ROE is -0.78%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, CRDF is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check CRNX's competition here
CRDF vs MYOV Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, CRDF is priced at $2.51, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas MYOV's P/E ratio is -14.05. In terms of profitability, CRDF's ROE is -0.78%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, CRDF is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check MYOV's competition here
CRDF vs LGND Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, LGND has a market cap of 2.6B. Regarding current trading prices, CRDF is priced at $2.51, while LGND trades at $135.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas LGND's P/E ratio is -18.57. In terms of profitability, CRDF's ROE is -0.78%, compared to LGND's ROE of -0.16%. Regarding short-term risk, CRDF is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check LGND's competition here
CRDF vs MIRM Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, MIRM has a market cap of 2.6B. Regarding current trading prices, CRDF is priced at $2.51, while MIRM trades at $52.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas MIRM's P/E ratio is -32.43. In terms of profitability, CRDF's ROE is -0.78%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, CRDF is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check MIRM's competition here
CRDF vs XENE Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, XENE has a market cap of 2.5B. Regarding current trading prices, CRDF is priced at $2.51, while XENE trades at $33.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas XENE's P/E ratio is -10.30. In terms of profitability, CRDF's ROE is -0.78%, compared to XENE's ROE of -0.32%. Regarding short-term risk, CRDF is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check XENE's competition here
CRDF vs RXRX Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, RXRX has a market cap of 2.5B. Regarding current trading prices, CRDF is priced at $2.51, while RXRX trades at $5.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas RXRX's P/E ratio is -3.22. In terms of profitability, CRDF's ROE is -0.78%, compared to RXRX's ROE of -0.75%. Regarding short-term risk, CRDF is more volatile compared to RXRX. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check RXRX's competition here
CRDF vs KNSA Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, KNSA has a market cap of 2.4B. Regarding current trading prices, CRDF is priced at $2.51, while KNSA trades at $32.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas KNSA's P/E ratio is 659.00. In terms of profitability, CRDF's ROE is -0.78%, compared to KNSA's ROE of +0.01%. Regarding short-term risk, CRDF is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check KNSA's competition here
CRDF vs NAMS Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, NAMS has a market cap of 2.4B. Regarding current trading prices, CRDF is priced at $2.51, while NAMS trades at $21.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas NAMS's P/E ratio is -11.77. In terms of profitability, CRDF's ROE is -0.78%, compared to NAMS's ROE of -0.33%. Regarding short-term risk, CRDF is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check NAMS's competition here
CRDF vs PRVB Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, CRDF is priced at $2.51, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas PRVB's P/E ratio is -16.43. In terms of profitability, CRDF's ROE is -0.78%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, CRDF is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check PRVB's competition here
CRDF vs NAMSW Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, NAMSW has a market cap of 2.3B. Regarding current trading prices, CRDF is priced at $2.51, while NAMSW trades at $10.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas NAMSW's P/E ratio is N/A. In terms of profitability, CRDF's ROE is -0.78%, compared to NAMSW's ROE of -0.33%. Regarding short-term risk, CRDF is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check NAMSW's competition here
CRDF vs LBPH Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, CRDF is priced at $2.51, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas LBPH's P/E ratio is -26.66. In terms of profitability, CRDF's ROE is -0.78%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, CRDF is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check LBPH's competition here
CRDF vs ARWR Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, ARWR has a market cap of 2.3B. Regarding current trading prices, CRDF is priced at $2.51, while ARWR trades at $16.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas ARWR's P/E ratio is -13.28. In terms of profitability, CRDF's ROE is -0.78%, compared to ARWR's ROE of -0.46%. Regarding short-term risk, CRDF is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check ARWR's competition here
CRDF vs BLTE Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, BLTE has a market cap of 2.3B. Regarding current trading prices, CRDF is priced at $2.51, while BLTE trades at $69.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas BLTE's P/E ratio is -51.32. In terms of profitability, CRDF's ROE is -0.78%, compared to BLTE's ROE of -0.32%. Regarding short-term risk, CRDF is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check BLTE's competition here
CRDF vs DICE Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, CRDF is priced at $2.51, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas DICE's P/E ratio is -21.91. In terms of profitability, CRDF's ROE is -0.78%, compared to DICE's ROE of +0.56%. Regarding short-term risk, CRDF is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check DICE's competition here
CRDF vs APGE Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, APGE has a market cap of 2.2B. Regarding current trading prices, CRDF is priced at $2.51, while APGE trades at $37.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas APGE's P/E ratio is -10.31. In terms of profitability, CRDF's ROE is -0.78%, compared to APGE's ROE of -0.19%. Regarding short-term risk, CRDF is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check APGE's competition here
CRDF vs GLPG Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, GLPG has a market cap of 2.2B. Regarding current trading prices, CRDF is priced at $2.51, while GLPG trades at $33.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas GLPG's P/E ratio is -6.66. In terms of profitability, CRDF's ROE is -0.78%, compared to GLPG's ROE of -0.10%. Regarding short-term risk, CRDF is more volatile compared to GLPG. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check GLPG's competition here
CRDF vs IDYA Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, IDYA has a market cap of 2.2B. Regarding current trading prices, CRDF is priced at $2.51, while IDYA trades at $25.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas IDYA's P/E ratio is -6.85. In terms of profitability, CRDF's ROE is -0.78%, compared to IDYA's ROE of -0.29%. Regarding short-term risk, CRDF is more volatile compared to IDYA. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check IDYA's competition here
CRDF vs IBRX Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, IBRX has a market cap of 2.2B. Regarding current trading prices, CRDF is priced at $2.51, while IBRX trades at $2.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas IBRX's P/E ratio is -4.21. In terms of profitability, CRDF's ROE is -0.78%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, CRDF is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check IBRX's competition here
CRDF vs CNTA Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, CNTA has a market cap of 2.1B. Regarding current trading prices, CRDF is priced at $2.51, while CNTA trades at $16.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas CNTA's P/E ratio is -8.55. In terms of profitability, CRDF's ROE is -0.78%, compared to CNTA's ROE of -0.57%. Regarding short-term risk, CRDF is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check CNTA's competition here
CRDF vs CALT Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, CRDF is priced at $2.51, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas CALT's P/E ratio is -22.73. In terms of profitability, CRDF's ROE is -0.78%, compared to CALT's ROE of -1.67%. Regarding short-term risk, CRDF is more volatile compared to CALT. This indicates potentially higher risk in terms of short-term price fluctuations for CRDF.Check CALT's competition here
CRDF vs FOLD Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, FOLD has a market cap of 2.1B. Regarding current trading prices, CRDF is priced at $2.51, while FOLD trades at $6.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas FOLD's P/E ratio is -56.92. In terms of profitability, CRDF's ROE is -0.78%, compared to FOLD's ROE of -0.20%. Regarding short-term risk, CRDF is less volatile compared to FOLD. This indicates potentially lower risk in terms of short-term price fluctuations for CRDF.Check FOLD's competition here
CRDF vs AGIO Comparison August 2025
CRDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRDF stands at 167M. In comparison, AGIO has a market cap of 2.1B. Regarding current trading prices, CRDF is priced at $2.51, while AGIO trades at $36.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRDF currently has a P/E ratio of -2.89, whereas AGIO's P/E ratio is 3.13. In terms of profitability, CRDF's ROE is -0.78%, compared to AGIO's ROE of +0.43%. Regarding short-term risk, CRDF is less volatile compared to AGIO. This indicates potentially lower risk in terms of short-term price fluctuations for CRDF.Check AGIO's competition here